Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-1 envelope evolution and vaccine efficacy.

D E Mosier1

  • 1Department of Immunology (IMM7), The Scripps Research Institute, La Jolla, CA 92037, USA. dmosier@scripps.edu

Current Drug Targets. Infectious Disorders
|June 25, 2005
PubMed
Summary

Early HIV-1 variants selected by neutralizing antibodies may evolve resistance. However, vaccination may still reduce viral load and set point during primary infection, impacting long-term disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thymus-independent antigens: complexity of B-lymphocyte activation revealed.

Immunology today·2014
Same author

Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.

Journal of virology·2009
Same author

Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Journal of virology·2005
Same author

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.

Journal of virology·2001
Same author

Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy.

Journal of acquired immune deficiency syndromes (1999)·2000
Same author

Human xenograft models for virus infection.

Virology·2000

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Human immunodeficiency virus type 1 (HIV-1) transmission selects for specific envelope variants.
  • These early variants utilize CCR5, bind it differently, and have shorter variable regions and fewer glycosylation sites than later strains.

Purpose of the Study:

  • To investigate the impact of early antibody selection pressure on HIV-1 evolution and disease progression.
  • To determine if HIV-1 can rapidly escape vaccine-induced antibody responses.

Main Methods:

  • Analysis of HIV-1 envelope properties selected during early transmission.
  • Review of recent reports on HIV-1 evolution and antibody escape.

Main Results:

  • HIV-1 rapidly evolves to escape antibody selection with minimal loss of entry fitness.
  • Early selection pressure from neutralizing antibodies may not prevent viral escape.

Conclusions:

  • Vaccine-induced antibody responses may be less impactful due to viral evolution.
  • Durable vaccine effects are predicted to manifest as reduced peak viremia and viral set point.

Related Experiment Videos